Verastem, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 87.37 million compared to USD 73.81 million a year ago. Basic loss per share from continuing operations was USD 3.96 compared to USD 4.57 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.38 USD | +1.79% | -4.67% | +15.23% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 18 | Verastem Oncology Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.23% | 237M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- VSTM Stock
- News Verastem, Inc.
- Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023